Related Experiment Video
Updated: Jun 5, 2026

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening
Published on: April 15, 2017
Plasticizer-responsive molecular axes in heart failure: a subtype-aware toxicogenomic framework relevant to
Zhaoxia Wang1, Yaosheng Wang2, Saihua Wang1
1Department of Cardiology, Shanghai Pudong New Area Zhoupu Hospital (Shanghai Health Medical College Affiliated Zhoupu Hospital), No.1500 Zhou Yuan Road, Pudong New District, Shanghai 201318, China.
Abstract:
Environmental exposure to synthetic chemicals has been associated with cardiovascular risk, yet mechanistic connections between real-world chemical mixtures and heart failure heterogeneity remain incompletely characterized. Here we present a mixture-aware toxicogenomic framework that integrates multi-cohort human cardiac transcriptomes with function-based grouping of 37 plasticizers. Using multi-resource, consensus-derived target profiles, we organized plasticizers into six functional clusters, enabling classification beyond chemical structure. Rather than relying on curated disease gene sets or single-cohort differential expression thresholds, we used a cross-validated, one-vs-rest machine learning strategy to derive subtype-resolved heart failure (HF) signatures directly from multi-cohort transcriptomes and used these reproducible signatures as an anchor for exposure-oriented mechanistic interpretation. We prioritized cross-cohort generalizability and signature stability by focusing on subtype-discriminative genes that recur consistently across validation iterations. Integrative analyses suggested associations between plasticizer clusters and HF-relevant pathogenic axes, including inflammatory remodeling, metabolic stress, and extracellular matrix processes, with subtype-resolved enrichment patterns consistent with VEGF/MAPK and hormonal signaling in dilated cardiomyopathy (DCM) and TNF/IL-17 and the diabetes-associated AGE-RAGE axis in ischemic cardiomyopathy (ICM). Shared signals included matrix remodeling and MMP-related programs across both subtypes. Overall, this scalable framework provides interpretable exposure-linked disease axes to support hypothesis generation in environmental cardiotoxicity and to inform consideration of chemical mixtures in cardiovascular risk assessment and monitoring.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Heart Failure II: Pathophysiology
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Drug Toxicity: Risk factors
